Circulating tumor cells (CTCs) are rare tumor cells released from primary, metastatic, or
recurrent tumors in the peripheral blood of cancer patients. CTCs isolation from peripheral …

Eight million people die of cancer each year and 90% of deaths are caused by systemic
disease. Circulating tumor cells (CTCs) contribute to the formation of metastases and thus …

Most cancer deaths arise from metastases as a result of circulating tumor cells (CTCs)
spreading from the primary tumor to vital organs. Despite progress in cancer prognosis, the …

Real-time monitoring of cancer cells' phenotypic evolution during therapy can provide vital
tumour biology information for treatment management. Circulating tumour cell (CTC) …

Cutaneous melanoma is one of the highest incident-rate cancers with increasing prevalence
in Western societies. Despite the advent of new approved therapeutics, the 5-year overall …

Ewing sarcoma (ES) is a highly aggressive bone and soft-tissue tumor with peak incidence
among adolescents and young adults. Despite advances in local control and systemic …

The invasive nature of surgical biopsies deters sequential application, and single biopsies
often fail to reflect tumor dynamics, intratumor heterogeneity and drug sensitivities likely to …

Liquid biopsy is a common term referring to circulating tumor cells and other biomarkers,
such as circulating tumor DNA (ctDNA) or extracellular vesicles. Liquid biopsy presents a …

Melanomas have increased in global incidence and are the leading cause of skin cancer
deaths. Whilst the majority of early-stage, non-metastatic melanomas can be cured with …

Melanoma heterogeneity is a hurdle in metastatic disease management. Although the
advent of targeted therapy has significantly improved patient outcomes, the occurrence of …